Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07311941

Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event

Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).

Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.

This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hyperlipidemia Cardio Vascular Disease Dyslipidemias Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Prince of Wales Hospital

Shatin, New Terrritories, 999077, Hong Kong

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18
  • (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
  • (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease

Exclusion criteria

  • Inability to provide valid consent by the patient or his legal guardian
  • Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
  • Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.

Treatment and study plan

Primary outcomes

  1. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Baseline

    Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline

  2. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: week 8

    Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8

  3. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Week 26

    Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26

  4. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Week 52

    Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52

  5. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Baseline

    Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline

  6. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Week 8

    Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8

  7. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Week 26

    Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26

  8. Low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Week 52

    Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52

Secondary outcomes

  1. Rate of subject meeting LDL-C target

    Time frame: Week 26

    Proportion of patients meeting prespecified LDL-C goals (>50% reduction from baseline) at week 26.

  2. Rate of subject meeting LDL-C target

    Time frame: Week 26

    Proportion of patients meeting prespecified LDL-C goals (<1.4mmol/l) at week 26.

  3. Rate of subject meeting LDL-C target

    Time frame: Week 26

    Proportion of patients meeting prespecified LDL-C goals (<1.8mmol/L) at week 26.

  4. 12-Item Short Form Survey (SF-12)

    Time frame: Baseline

    Patient's quality of life as measured by SF-12 at baseline

  5. 12-Item Short Form Survey (SF-12)

    Time frame: Week 8

    Patient's quality of life as measured by SF-12 at week 8

  6. 12-Item Short Form Survey (SF-12)

    Time frame: Week 26

    Patient's quality of life as measured by SF-12 at week 26

  7. 12-Item Short Form Survey (SF-12)

    Time frame: Week 52

    Patient's quality of life as measured by SF-12 at week 52

  8. Rate of major adverse cardiovascular event (MACE)

    Time frame: Baseline

    Occurrence of any major adverse cardiovascular event (MACE) at Baseline

  9. Rate of major adverse cardiovascular event (MACE)

    Time frame: Week 8

    Occurrence of any major adverse cardiovascular event (MACE) at week 8

  10. Rate of major adverse cardiovascular event (MACE)

    Time frame: Week 26

    Occurrence of any major adverse cardiovascular event (MACE) at week 26

  11. Rate of major adverse cardiovascular event (MACE)

    Time frame: Week52

    Occurrence of any major adverse cardiovascular event (MACE) at week 52

  12. Modification of lipid lowering therapy (LLT)

    Time frame: Week 8

    Modification of lipid lowering therapy (LLT) at week 8

  13. Modification of lipid lowering therapy (LLT)

    Time frame: Week 26

    Modification of lipid lowering therapy (LLT) at week 26

  14. Modification of lipid lowering therapy (LLT)

    Time frame: Week 52

    Modification of lipid lowering therapy (LLT) at week 52

  15. Lipid Lowering Therapy adherence

    Time frame: Week 52

    LLT adherence, expressed in proportion of days covered, at week 52

  16. Tolerability of Lipid Lowering Therapy

    Time frame: Week 52

    Rate of adverse drug event reported by subjects on lipid lowering therapy at week 52

Study contacts

Contact information is provided by the study sponsor or research team.

Guangming Tan

CONTACT

[email protected]

852-35051518

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study

Acronym: REDUCE-Lipid

Important dates

Study start
2024
Primary completion
2030
Study completion
2031
First posted
Dec 31, 2025
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.